Cloudways Demonstrates Growth Ambitions with Customer Momentum, New Features, and Key Executive Hires
2.6.2022 10:00:00 EEST | Business Wire | Press release
Cloudways (cloudways.com), the leading cloud hosting provider focused on simplicity, flexibility, and performance, announces significant customer momentum ahead of their presence at WordCamp Europe. Cloudways’ announcements at WordCamp Europe include SafeUpdates (in beta), new automations that manage WordPress updates at scale, and partnership with Astra Pro, a collaboration allowing users to build websites faster and easier than ever before.
Cloudways supports over 70k customers and 500K+ websites and was recently rated by G2 as the best cloud hosting company for SMBs with a rating of 4.8 out of 5. Additionally, Cloudways has strengthened its executive team with the hire of ex-Microsoft executive Paul Haverstock as VP of Engineering, Bluehost executive Suhaib Zaheer as COO, and AWS executive Tom Erskine as CMO. Cloudways has significantly grown in size to more than 280 employees, with its global mindset reflected in an employee base coming from 20+ countries.
Cloudways focuses on giving agencies, SMBs, e-commerce providers, and individuals a hassle-free, premium experience to help them grow their business with both peace of mind and improved productivity. The Cloudways platform features >99.9% uptime, fast page load times, pro-active app monitoring, dedicated workflows, leading security with add-ons from Cloudflare, and 24/7 premium support. Great value and flexibility are also key platform features with pay-as-you-go plans offered from cloud providers including AWS, Google Cloud, Linode, Vultur, and Digital Ocean and a choice of 65+ Data Center locations.
SafeUpdates, which is being launched in beta, is Cloudways’ newest feature and will enable agencies and developers to update their WordPress websites both automatically and on demand. The workflow secures a backup, performs advanced visual regression testing and performance checks on both staging and live, and then deploys selected updates to production or automatically rolls back the changes in case of any issues. SafeUpdates allows agencies and developers to automate their work, focus on their business, and upsell maintenance services with confidence.
Cloudways’ partnership with Astra Pro is part of a series of collaborations the company has made in recent months to enhance WordPress simplicity and ensure maximum performance and security on its platform. Cloudways has worked closely with Cloudflare, OceanWP, Divi, and OCP among others to offer a seamless, no-code digital experience for agencies and developers to build and secure WordPress websites.
“Cloudways is both growing as a company and building significant momentum in the cloud hosting industry,” said Aaqib Gadit, Co-Founder and CEO of Cloudways. “The recent addition of Suhaib, Tom, and Paul to our leadership team shows the growth plans and ambition we have for Cloudways. At Cloudways, we are deeply focused on being a trusted partner to our customers and are continually innovating to save them both time and money while delivering a great user experience.”
To learn more, visit Cloudways’ booth at WordCamp Europe at https://www.cloudways.com/en/wordcamp-europe.php
About Cloudways:
Founded in 2012, Cloudways is an intuitive, one-click managed cloud hosting platform that hosts over 50,000 servers globally. G2’s Best Managed Hosting Provider for 2021, the platform lets users host WordPress and WooCommerce websites on top of a variety of cloud-hosting providers, including Google Cloud, Amazon Web Services, DigitalOcean, Vultr, and Linode. The platform features a web app management function that easily launches cloud servers for the deployment of WordPress, Magento, and PHP. Visit the company website at https://www.cloudways.com/en/about_us.php
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005120/en/
Contact information
Cloudways Media Contact:
Lauren Perry
SlicedBrand for Cloudways
lauren@slicedbrand.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom